1-8 of 8
Francois Romagne, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Anti-KIR Antibody Enhancement Of Anti-Lymphoma Activity Of Natural Killer Cells As Monotherapy and In Combination With Anti-CD20 Antibodies

Holbrook E Kohrt, MD, PhD, Ariane Thielens, Aurelien Marabelle, MD, MSc, Idit Sagiv Barfi, Caroline Sola, Fabien Chanuc, Nicolas Fuseri, Cécile Bonnafous, Debra K Czerwinski, Amanda Rajapaksa, Erin Waller, Sophie Ugolini, PhD, Eric Vivier, PhD, Francois Romagne, PhD, Ronald Levy, MD, Pascale Andre, PhD, Mathieu Blery, PhD
Journal: Blood
Blood (2013) 122 (21): 4417.
https://doi.org/10.1182/blood.V122.21.4417.4417
Published: 2013
Journal Articles

Natural Killer Cells Recovery After Consolidation Chemotherapy in Elderly Patients with Acute Myeloid Leukemia (AML)

Jerome Rey, MD, Nicolas Anfossi, PhD, Pascale Andre, PhD, Jean-Marie Boher, Florence Orlanducci, Violette Breso, Valentine Perri, Thomas Prebet, MD, PhD, Aude Charbonnier, MD, PhD, Eloïse Perrot, Francois Romagne, PhD, Norbert Vey, MD, Daniel Olive, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 2189.
https://doi.org/10.1182/blood.V118.21.2189.2189
Published: 2011
Journal Articles

Long Lasting Alteration of Natural Killer Cells Post-Chemotherapy in Elderly Patients with Acute Myeloid Leukemia (AML).

Daniel Olive, MD, PhD, Nicolas Anfossi, Pascale Andre, PhD, Jerome Rey, Florence Orlanducci, Violette Breso, Valentine Peri, Thomas Prébet, MD, Aude Charbonnier, MD, PhD, Eloise Perrot, Francois Romagne, PhD, Norbert Vey
Journal: Blood
Blood (2009) 114 (22): 1653.
https://doi.org/10.1182/blood.V114.22.1653.1653
Published: 2009
Journal Articles

Characterization of Early Natural Killer Cell Reconstitution Following Autologous Transplantation in Multiple Myeloma.

Don Benson, MD, PhD, Courtney E Bakan, Lana Alghothani, Craig C. Hofmeister, MD, Yvonne A Efebera, M.D., Megan K Smith, MS, CNP, RN, Carli N Greenfield, Pascale Andre, PhD, Patrick Squiban, Francois Romagne, PhD, Michael A. Caligiuri, M.D., Steven M Devine, MD
Journal: Blood
Blood (2009) 114 (22): 4641.
https://doi.org/10.1182/blood.V114.22.4641.4641
Published: 2009
Journal Articles

A Phase I Study of the Anti-Natural Killer Inhibitory Receptor (KIR) Monoclonal Antibody (1-7F9, IPH2101) in Elderly Patients with Acute Myeloid Leukemia (AML): Clinical and Immunological Effects of a Single Dose Followed by Repeated Dosing.

Norbert Vey, Jean-Henri Bourhis, MD, PhD, Herve Dombret, MD, PhD, Dominique Bordessoule, Thomas Prébet, MD, Aude Charbonnier, Stephane de Botton, Nicolas Boissel, MD, PhD, Christine d'Arnoux, MD, Francois Romagne, PhD, Pascale Andre, PhD, Jerome Tiollier, Patrick Squiban, Didier Blaise, Daniel Olive, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 632.
https://doi.org/10.1182/blood.V114.22.632.632
Published: 2009
Journal Articles

IPH1101, the First Specific γδ T Cell Agonist, Shows Potent Immuno-Biological Efficacy in Low Grade Follicular Lymphoma Patients When Combined with Rituximab: Results From a Phase II Study.

Claire Lucas, Sophie Ingoure, Elodie Soule, Bruna Faria, Fabien Audibert, Mathieu Blery, Lucile Beautier, Francois Romagne, PhD, Sylvie de Micheaux, MD, Helene Sicard, PhD
Journal: Blood
Blood (2009) 114 (22): 583.
https://doi.org/10.1182/blood.V114.22.583.583
Published: 2009
Journal Articles

IPH2101, a Novel Anti-Inhibitory KIR Monoclonal Antibody, and Lenalidomide Combine to Enhance the Natural Killer (NK) Cell Versus Multiple Myeloma (MM) Effect.

Don Benson, MD, PhD, Courtney E Bakan, Shuhong Zhang, PhD, Lana Alghothani, Jing Liang, Craig Hofmeister, MD, Shivani Srivastava, MD, Megan K Smith, MS, CNP, RN, Carli N Greenfield, Pascale Andre, PhD, Patrick Squiban, MD, Francois Romagne, PhD, Michael A. Caligiuri, M.D., Sherif Farag, MBBS, PhD
Journal: Blood
Blood (2009) 114 (22): 3870.
https://doi.org/10.1182/blood.V114.22.3870.3870
Published: 2009
Journal Articles

Anti-KIR (1-7F9): A Fully Human Monoclonal Antibody (mAb) That Blocks KIR2DL1, −2 and −3, Promoting Natural Killer (NK) Cell-Mediated Lysis of Tumor Cells In Vitro and In Vivo.

Nicolai Wagtmann, PhD, Pascale Andre, PhD, Stefan Zahn, PhD, Pieter Spee, PhD, Nicolas Anfossi, PhD, Laurent Gauthier, PhD, Bradley W. Blaser, PhD, Michael A. Caligiuri, MD, Marusca Capanni, Loredana Ruggeri, PhD, Andrea Velardi, MD, Francois Romagne, PhD
Journal: Blood
Blood (2007) 110 (11): 582.
https://doi.org/10.1182/blood.V110.11.582.582
Published: 2007